cd-73

PD-L1/CD-73-IN-1 (compound CC-5) is an inhibitor of PD-L1 and CD73, with IC50 values of 6 nM and 0.773 μM, respectively. It effectively inhibits tumor cell growth both in vitro and in vivo.

CD73-IN-5 is a highly potent and selective small molecule inhibitor of CD73, demonstrating non-nucleotide characteristics. It exerts its inhibitory effects with a remarkable IC50 value of 19 nM.

MethADP (Adenosine 5'-(α,β-methylene)diphosphate) is a specific CD73 inhibitor that inhibits the enzyme ecto-5′-nucleotidase (ecto), which has been used in the study of neurological and cardiovascular diseases.

PSB-12379 ditriethylamine salt, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).

CD73-IN-1 is a CD73 inhibitor with anticancer activity.

CD73-IN-3 (LY-3475070) is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.

CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor.

AB-680, a highly potent, reversible, and selective inhibitor of CD73 (an ectonucleotidase, Ki: 4.9 pM for hCD73) with anti-tumor activity, displays >10,000-fold selectivity over related ectonucleotidases CD39.

MethADP is a specific CD73 inhibitor.

PSB-12379 is a potent inhibitor of Ecto-5'-Nucleotidase (CD73)(Kis of 9.03 nM (rat) and 2.21 nM (human)).

CD73-IN-18 (compound 35j) is an orally effective inhibitor of the extracellular 5'-nucleotidase (CD73) enzyme. It can be utilized in anticancer research.

ZM522 is a CD73 inhibitor with an IC50 value of 0.56 μM. It effectively increases interferon-gamma (INF-γ) levels and enhances immune activity by modulating T cell activation. ZM522 holds potential for research in immunology and anti-cancer fields.

CD73-IN-19 (Compound 4ab) is an inhibitor of CD73, demonstrating a 44% inhibition rate of CD73 enzyme activity at 100 μM. It entirely counters T cell proliferation blockade triggered by TCR activation (induced by CD73 activity) at 10 μM and 100 μM and inhibits hA2A receptor activity in HEK-293 cells with a Ki of 3.31 μM. CD73-IN-19 holds potential for research in the field of immune diseases.

PSB-24000 (Compound 27) is a selective ecto-5'-nucleotidase (CD73) inhibitor with a Ki value of 563 nM for inhibiting human CD73, and a Ki of 481 nM in membrane-bound CD73 in triple-negative breast cancer cells. It disrupts CD73’s recognition and action on substrate AMP, preventing AMP-induced immunosuppressive and pro-cancer adenosine production. PSB-24000 is promising for cancer research.

XC-12 is an orally active, potent small-molecule inhibitor of CD73 (an immune checkpoint), with IC50 values of 12.36 nM for the soluble form and 1.29 nM for the membrane-bound form. XC-12 holds promise for cancer research.

GMPCP (GpCp) trisodium (Compound 7 trisodium) is a guanine derivative and CD73 inhibitor, with Ki values of 1110 nM for rat soluble CD73 and 410 nM for human soluble CD73. This compound is applicable in cancer research.

PSB-0963 is a selective competitive extracellular 5'-nucleotidase (eN/CD73) inhibitor with a Ki value of 150 nM for rat extracellular 5'-nucleotidase. It exhibits greater selectivity compared to other extracellular nucleotidases (NTPDases 1-3) and P2Y receptors. PSB-0963 is applicable in cancer research.

CD73-IN-21 (Compound 12f) is an inhibitor of ecto-5′-nucleotidase (CD73), with Ki values of 20 nM for hCD73 and 302 nM for mCD73. It is applicable in research related to cancers, such as breast cancer.

COPCP trisodium (Compound 7a) is a potent and selective inhibitor of the ecto-5'-nucleotidase CD73. By blocking CD73-mediated adenosine production, it reduces adenosine's inhibitory effects on immune cells. COPCP trisodium shows promise for cancer research.

OP-5244 has comparable potency to bisphosphonic acid series and targets CD73.

CD73-IN-7 is a potent CD73 inhibitor used for preparing medications for tumor-related diseases. CD73 catalyzes the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), inducing immunosuppressive effects and promoting tumor proliferation and/or metastasis [1].

CD73-IN-13 is able to be used in a medicament preparing for tumor-related diseases. CD73-IN-13 is a potent inhibitor of CD73 which is closely associated with tumor growth, angiogenesis and metastasis [1].

CD73-IN-9, a potent CD73 inhibitor, is used in preparing medication for tumor-related diseases. CD73 catalyzes the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), which can induce immunosuppressive effects and promote tumor proliferation and/or metastasis [1].

CD73-IN-10 can be used in preparing tumor-related diseases medicament. CD73-IN-10 is a potent CD73 inhibitor that can catalyze the adenosine production from extracellular 5'-phosphate adenosine (5'-AMP). Adenosine induces immunosuppression and can promote tumor proliferation and/or metastasis [1].